Press Releases

Investor Resources
Contact Us
Investor ResourcesPress Releases

Press Releases

Cardiol Therapeutics Announces Year-End 2021 Update on Operations


March 24, 2022

Cardiol Therapeutics to Participate in Cantor Fitzgerald’s Virtual Rare Orphan Disease Summit


March 22, 2022

Cardiol Therapeutics Appoints Jennifer M. Chao to its Board of Directors


March 15, 2022

Cardiol Therapeutics Receives Clearance from the FDA and Regulatory Agencies in Brazil and Mexico for Important Protocol Amendments Designed to Expedite Patient Enrollment in the LANCER Trial


March 1, 2022

Cardiol Therapeutics Appoints Thought Leaders in Cardiovascular Medicine to its Scientific Advisory Board


January 19, 2022

Cardiol Therapeutics Announces Closing of US$50 Million Public Offering


November 5, 2021

Cardiol Therapeutics Announces Pricing of Public Offering of Units


November 3, 2021

Cardiol Therapeutics Files Preliminary Prospectus Supplement for Proposed Public Offering of Units


November 2, 2021

Cardiol Therapeutics Receives Health Canada Approval for Phase II Clinical Trial of CardiolRx™ for Acute Myocarditis


October 25, 2021

2025 Cardiol Therapeutics. All right reserved.